BACKGROUND: The benefits of proton beam craniospinal irradiation (PrBCSI) in children have been extensively reported in dosimetric studies. However, there is limited clinical evidence supporting the use of PrBCSI. We compared the acute toxicity of PrBCSI relative to that of conventional photon beam CSI (PhBCSI) in children with brain tumours. MATERIAL AND METHODS: We prospectively evaluated the haematological and gastrointestinal toxicities in 30 patients who underwent PrBCSI between April 2008 and December 2012. As a reference group, we retrospectively evaluated the medical records of 13 patients who underwent PhBCSI between April 2003 and April 2012. The median follow-up time from starting CSI was 22 months (range 2-118 months). The mean irradiation dose was 32.1 Gy (range 23.4-39.6 Gy) and 29.4 CGE (cobalt grey equivalents; range 19.8-39.6), in the PrBCSI and PhBCSI groups, respectively (p = 0.236). RESULTS: There was no craniospinal fluid space relapse after curative therapy in either group of patients. Thrombocytopenia was less severe in the PrBCSI group than in the PhBCSI group (p = 0.012). The recovery rates of leukocyte and platelet counts measured one month after treatment were significantly greater in the PrBCSI group than in the PhBCSI group (p = 0.003 and p = 0.010, respectively). Diarrhoea was reported by 23% of patients in the PhBCSI group versus none in the PrBCSI group (p = 0.023). CONCLUSIONS: The incidence rates of thrombocytopenia and diarrhoea were lower in the PrBCSI group than in the PhBCSI group. One month after completing treatment, the recovery from leukopenia and thrombocytopenia was better in patients treated with PrBCSI than in those treated with PhBCSI.
BACKGROUND: The benefits of proton beam craniospinal irradiation (PrBCSI) in children have been extensively reported in dosimetric studies. However, there is limited clinical evidence supporting the use of PrBCSI. We compared the acute toxicity of PrBCSI relative to that of conventional photon beam CSI (PhBCSI) in children with brain tumours. MATERIAL AND METHODS: We prospectively evaluated the haematological and gastrointestinal toxicities in 30 patients who underwent PrBCSI between April 2008 and December 2012. As a reference group, we retrospectively evaluated the medical records of 13 patients who underwent PhBCSI between April 2003 and April 2012. The median follow-up time from starting CSI was 22 months (range 2-118 months). The mean irradiation dose was 32.1 Gy (range 23.4-39.6 Gy) and 29.4 CGE (cobalt grey equivalents; range 19.8-39.6), in the PrBCSI and PhBCSI groups, respectively (p = 0.236). RESULTS: There was no craniospinal fluid space relapse after curative therapy in either group of patients. Thrombocytopenia was less severe in the PrBCSI group than in the PhBCSI group (p = 0.012). The recovery rates of leukocyte and platelet counts measured one month after treatment were significantly greater in the PrBCSI group than in the PhBCSI group (p = 0.003 and p = 0.010, respectively). Diarrhoea was reported by 23% of patients in the PhBCSI group versus none in the PrBCSI group (p = 0.023). CONCLUSIONS: The incidence rates of thrombocytopenia and diarrhoea were lower in the PrBCSI group than in the PhBCSI group. One month after completing treatment, the recovery from leukopenia and thrombocytopenia was better in patients treated with PrBCSI than in those treated with PhBCSI.
Authors: Susan L McGovern; M Fatih Okcu; Mark F Munsell; Nancy Kumbalasseriyil; David R Grosshans; Mary F McAleer; Murali Chintagumpala; Soumen Khatua; Anita Mahajan Journal: Int J Radiat Oncol Biol Phys Date: 2014-10-11 Impact factor: 7.038
Authors: Brian De; Michael D Kinnaman; Leonard H Wexler; Kim Kramer; Suzanne L Wolden Journal: Pediatr Blood Cancer Date: 2017-07-11 Impact factor: 3.167
Authors: Derek S Tsang; Louise Murray; Vijay Ramaswamy; Michal Zapotocky; Uri Tabori; Ute Bartels; Annie Huang; Peter B Dirks; Michael D Taylor; Cynthia Hawkins; Eric Bouffet; Normand Laperriere Journal: Neuro Oncol Date: 2019-03-18 Impact factor: 12.300
Authors: Jillian R Gunther; Ahmad R Rahman; Wenli Dong; Zeinab Abou Yehia; Partow Kebriaei; Gabriela Rondon; Chelsea C Pinnix; Sarah A Milgrom; Pamela K Allen; Bouthaina S Dabaja; Grace L Smith Journal: Pract Radiat Oncol Date: 2017-05-10
Authors: Gyu Sang Yoo; Jeong Il Yu; Sungkoo Cho; Youngyih Han; Yoonjin Oh; Do Hoon Lim; Hee Rim Nam; Ji-Won Lee; Ki-Woong Sung; Hyung Jin Shin Journal: Cancer Res Treat Date: 2021-10-15 Impact factor: 5.036
Authors: Sergio Jaramillo; David R Grosshans; Nancy Philip; Ali Varan; Canan Akyüz; Mary Frances McAleer; Anita Mahajan; Susan L McGovern Journal: Clin Transl Radiat Oncol Date: 2018-11-07